{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:44:15Z","timestamp":1792896255476,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81721002"],"award-info":[{"award-number":["81721002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Innovation Team and Talents Cultivation Program of the National Administration of Traditional Chinese Medicine","award":["ZYYCXTD-C-202005"],"award-info":[{"award-number":["ZYYCXTD-C-202005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Nonalcoholic steatohepatitis (NASH) is a progressive and inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocellular injury, inflammation, and fibrosis in various stages. More than 20% of patients with NASH will progress to cirrhosis. Currently, there is a lack of clinically effective drugs for treating NASH, as improving liver histology in NASH is difficult to achieve and maintain through weight loss alone. Hence, the present study aimed to investigate potential therapeutic drugs for NASH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>BMDMs and THP1 cells were used to construct an inflammasome activation model, and then we evaluated the effect of epalrestat on the NLRP3 inflammasome activation. Western blot, real-time qPCR, flow cytometry, and ELISA were used to evaluate the mechanism of epalrestat on NLRP3 inflammasome activation. Next, MCD-induced NASH models were used to evaluate the therapeutic effects of epalrestat in vivo. In addition, to evaluate the safety of epalrestat in vivo, mice were gavaged with epalrestat daily for 14 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Epalrestat, a clinically effective and safe drug, inhibits NLRP3 inflammasome activation by acting upstream of caspase-1 and inducing ASC oligomerization. Importantly, epalrestat exerts its inhibitory effect on NLRP3 inflammasome activation by inhibiting the activation of aldose reductase. Further investigation revealed that the administration of epalrestat inhibited NLRP3 inflammasome activation in <jats:italic>vivo<\/jats:italic>, alleviating liver inflammation and improving NASH pathology.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study indicated that epalrestat, an aldose reductase inhibitor, effectively suppressed NLRP3 inflammasome activation in <jats:italic>vivo<\/jats:italic> and in <jats:italic>vitro<\/jats:italic> and might be a new therapeutic approach for NASH.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s12967-023-04380-4","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T15:01:48Z","timestamp":1696690908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase"],"prefix":"10.1186","volume":"21","author":[{"given":"Wei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziying","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Long","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1032-8635","authenticated-orcid":false,"given":"Zhaofang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohe","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"issue":"1","key":"4380_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"12","key":"4380_CR2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, et al. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175\u201383.","journal-title":"JAMA"},{"issue":"7","key":"4380_CR3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"10290","key":"4380_CR4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, et al. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","journal-title":"Lancet"},{"issue":"6","key":"4380_CR5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","volume":"116","author":"CA Matteoni","year":"1999","unstructured":"Matteoni CA, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413\u20139.","journal-title":"Gastroenterology"},{"issue":"7","key":"4380_CR6","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696\u2013703.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"4380_CR7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","volume":"113","author":"M Noureddin","year":"2018","unstructured":"Noureddin M, et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am J Gastroenterol. 2018;113(11):1649\u201359.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"4380_CR8","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.23258","volume":"51","author":"RS O'Shea","year":"2010","unstructured":"O\u2019Shea RS, et al. Alcoholic liver disease. Hepatology. 2010;51(1):307\u201328.","journal-title":"Hepatology"},{"issue":"5","key":"4380_CR9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/liv.13270","volume":"37","author":"H Perazzo","year":"2017","unstructured":"Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 2017;37(5):634\u201347.","journal-title":"Liver Int"},{"issue":"8","key":"4380_CR10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1053\/j.gastro.2016.03.004","volume":"150","author":"G Lassailly","year":"2016","unstructured":"Lassailly G, et al. Perspectives on treatment for nonalcoholic steatohepatitis. Gastroenterology. 2016;150(8):1835\u201348.","journal-title":"Gastroenterology"},{"issue":"1","key":"4380_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s12072-019-10001-4","volume":"14","author":"KC Reimer","year":"2020","unstructured":"Reimer KC, et al. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int. 2020;14(1):8\u201323.","journal-title":"Hepatol Int"},{"issue":"2","key":"4380_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.e365.","journal-title":"Gastroenterology"},{"issue":"2","key":"4380_CR13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2016.09.012","volume":"66","author":"A Vitale","year":"2017","unstructured":"Vitale A, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017;66(2):412\u201323.","journal-title":"J Hepatol"},{"issue":"2","key":"4380_CR14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/cells10020210","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Berberine prevents disease progression of nonalcoholic steatohepatitis through modulating multiple pathways. Cells. 2021;10(2):210.","journal-title":"Cells"},{"issue":"5","key":"4380_CR15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-016-4049-x","volume":"61","author":"M Arrese","year":"2016","unstructured":"Arrese M, et al. Innate Immunity and Inflammation in NAFLD\/NASH. Dig Dis Sci. 2016;61(5):1294\u2013303.","journal-title":"Dig Dis Sci"},{"issue":"6037","key":"4380_CR16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","volume":"332","author":"JC Cohen","year":"2011","unstructured":"Cohen JC, et al. Human fatty liver disease: old questions and new insights. Science. 2011;332(6037):1519\u201323.","journal-title":"Science"},{"issue":"2","key":"4380_CR17","first-page":"246","volume":"119","author":"JJ Maher","year":"2009","unstructured":"Maher JJ. DAMPs ramp up drug toxicity. J Clin Invest. 2009;119(2):246\u20139.","journal-title":"J Clin Invest"},{"issue":"2","key":"4380_CR18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/hep.29523","volume":"67","author":"A Wree","year":"2018","unstructured":"Wree A, et al. NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice. Hepatology. 2018;67(2):736\u201349.","journal-title":"Hepatology"},{"issue":"7","key":"4380_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1872-034X.2011.00814.x","volume":"41","author":"DA Brenner","year":"2011","unstructured":"Brenner DA, et al. Non-alcoholic steatohepatitis-induced fibrosis: Toll-like receptors, reactive oxygen species and Jun N-terminal kinase. Hepatol Res. 2011;41(7):683\u20136.","journal-title":"Hepatol Res"},{"issue":"1","key":"4380_CR20","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","volume":"74","author":"S Gaul","year":"2021","unstructured":"Gaul S, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J Hepatol. 2021;74(1):156\u201367.","journal-title":"J Hepatol"},{"issue":"5","key":"4380_CR21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","volume":"18","author":"S Paik","year":"2021","unstructured":"Paik S, et al. An update on the regulatory mechanisms of NLRP3 inflammasome activation. Cell Mol Immunol. 2021;18(5):1141\u201360.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"4380_CR22","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157(5):1013\u201322.","journal-title":"Cell"},{"issue":"4","key":"4380_CR23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, et al. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 2017;42(4):245\u201354.","journal-title":"Trends Biochem Sci"},{"issue":"12","key":"4380_CR24","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/cr.2015.139","volume":"25","author":"WT He","year":"2015","unstructured":"He WT, et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1\u03b2 secretion. Cell Res. 2015;25(12):1285\u201398.","journal-title":"Cell Res"},{"key":"4380_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00050","author":"RW Grant","year":"2013","unstructured":"Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol. 2013. https:\/\/doi.org\/10.3389\/fimmu.2013.00050.","journal-title":"Front Immunol"},{"issue":"3","key":"4380_CR26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.molimm.2012.01.005","volume":"50","author":"GH Goossens","year":"2012","unstructured":"Goossens GH, et al. Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans. Mol Immunol. 2012;50(3):142\u20139.","journal-title":"Mol Immunol"},{"issue":"3","key":"4380_CR27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21(3):248\u201355.","journal-title":"Nat Med"},{"issue":"7","key":"4380_CR28","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C, et al. OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA. 2018;115(7):E1530-e1539.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"4380_CR29","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1002\/ptr.7214","volume":"35","author":"ZY Cui","year":"2021","unstructured":"Cui ZY, et al. Parthenolide, bioactive compound of Chrysanthemum parthenium L, ameliorates fibrogenesis and inflammation in hepatic fibrosis via regulating the crosstalk of TLR4 and STAT3 signaling pathway. Phytother Res. 2021;35(10):5680\u201393.","journal-title":"Phytother Res"},{"issue":"11","key":"4380_CR30","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/antiox10111850","volume":"10","author":"J Wei","year":"2021","unstructured":"Wei J, et al. Sulforaphane-mediated Nrf2 activation prevents radiation-induced skin injury through inhibiting the oxidative-stress-activated DNA damage and NLRP3 inflammasome. Antioxidants. 2021;10(11):1850.","journal-title":"Antioxidants"},{"issue":"1","key":"4380_CR31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12974-017-0980-9","volume":"14","author":"W Jiang","year":"2017","unstructured":"Jiang W, et al. Targeting the NLRP3 inflammasome to attenuate spinal cord injury in mice. J Neuroinflammation. 2017;14(1):207.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"4380_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12974-017-0895-5","volume":"14","author":"J Zeng","year":"2017","unstructured":"Zeng J, et al. Isoliquiritigenin alleviates early brain injury after experimental intracerebral hemorrhage via suppressing ROS- and\/or NF-\u03baB-mediated NLRP3 inflammasome activation by promoting Nrf2 antioxidant pathway. J Neuroinflammation. 2017;14(1):119.","journal-title":"J Neuroinflammation"},{"issue":"8","key":"4380_CR33","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson KV, et al. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"4380_CR34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1592\/phco.28.5.646","volume":"28","author":"MA Ramirez","year":"2008","unstructured":"Ramirez MA, Borja NL. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy. 2008;28(5):646\u201355.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"4380_CR35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.7326\/0003-4819-101-1-82","volume":"101","author":"DG Cogan","year":"1984","unstructured":"Cogan DG, et al. NIH conference Aldose reductase and complications of diabetes. Ann Intern Med. 1984;101(1):82\u201391.","journal-title":"Ann Intern Med"},{"key":"4380_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2016.04.006","volume":"54","author":"PF Kador","year":"2016","unstructured":"Kador PF, et al. Aldose reductase, ocular diabetic complications and the development of topical Kinostat (\u00ae). Prog Retin Eye Res. 2016;54:1\u201329.","journal-title":"Prog Retin Eye Res"},{"key":"4380_CR37","first-page":"CD002182","volume":"2","author":"M Airey","year":"2000","unstructured":"Airey M, et al. Aldose reductase inhibitors for the prevention and treatment of diabetic peripheral neuropathy. Cochrane Database Syst Rev. 2000;2:CD002182.","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl 2","key":"4380_CR38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-198600322-00010","volume":"32","author":"P Benfield","year":"1986","unstructured":"Benfield P. Aldose reductase inhibitors and late complications of diabetes. Drugs. 1986;32(Suppl 2):43\u201355.","journal-title":"Drugs"},{"issue":"1","key":"4380_CR39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41401-018-0043-5","volume":"40","author":"J He","year":"2019","unstructured":"He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db\/db mice through metabolic modulation. Acta Pharmacol Sin. 2019;40(1):86\u201397.","journal-title":"Acta Pharmacol Sin"},{"issue":"13","key":"4380_CR40","doi-asserted-by":"crossref","first-page":"6052","DOI":"10.1080\/07391102.2021.1875878","volume":"40","author":"S Choudhary","year":"2022","unstructured":"Choudhary S, Silakari O. Virtual screening of epalrestat mimicking selective ALR2 inhibitors from natural product database: auto pharmacophore, ADMET prediction and molecular dynamics approach. J Biomol Struct Dyn. 2022;40(13):6052\u201370.","journal-title":"J Biomol Struct Dyn"},{"key":"4380_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0167-x","author":"D Zheng","year":"2020","unstructured":"Zheng D, et al. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discov. 2020. https:\/\/doi.org\/10.1038\/s41421-020-0167-x.","journal-title":"Cell Discov"},{"issue":"9","key":"4380_CR42","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang Y, et al. NLRP3 inflammasome activation and cell death. Cell Mol Immunol. 2021;18(9):2114\u201327.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"4380_CR43","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","volume":"41","author":"Y He","year":"2016","unstructured":"He Y, et al. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2016;41(12):1012\u201321.","journal-title":"Trends Biochem Sci"},{"issue":"6151","key":"4380_CR44","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1126\/science.1240248","volume":"341","author":"N Kayagaki","year":"2013","unstructured":"Kayagaki N, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 2013;341(6151):1246\u20139.","journal-title":"Science"},{"issue":"7237","key":"4380_CR45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nature07710","volume":"458","author":"T Fernandes-Alnemri","year":"2009","unstructured":"Fernandes-Alnemri T, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature. 2009;458(7237):509\u201313.","journal-title":"Nature"},{"issue":"7","key":"4380_CR46","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1073\/pnas.0913087107","volume":"107","author":"EA Miao","year":"2010","unstructured":"Miao EA, et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc Natl Acad Sci USA. 2010;107(7):3076\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"4380_CR47","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","volume":"183","author":"FG Bauernfeind","year":"2009","unstructured":"Bauernfeind FG, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787\u201391.","journal-title":"J Immunol"},{"issue":"9","key":"4380_CR48","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.4049\/jimmunol.0900444","volume":"183","author":"Jr Harder","year":"2009","unstructured":"Harder Jr, et al. Activation of the Nlrp3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-\u03baB activation but proceeds independently of TLR signaling and P2X7 receptor1. J Immunol. 2009;183(9):5823\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"4380_CR49","doi-asserted-by":"crossref","first-page":"792","DOI":"10.4049\/jimmunol.0900173","volume":"183","author":"L Franchi","year":"2009","unstructured":"Franchi L, et al. Cutting edge: TNF-\u03b1 mediates sensitization to ATP and silica via the nlrp3 inflammasome in the absence of microbial stimulation1. J Immunol. 2009;183(2):792\u20136.","journal-title":"J Immunol"},{"issue":"12","key":"4380_CR50","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.imbio.2012.07.020","volume":"217","author":"K Schroder","year":"2012","unstructured":"Schroder K, et al. Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction. Immunobiology. 2012;217(12):1325\u20139.","journal-title":"Immunobiology"},{"issue":"6","key":"4380_CR51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, et al. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13(6):397\u2013411.","journal-title":"Nat Rev Immunol"},{"issue":"7237","key":"4380_CR52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature07725","volume":"458","author":"V Hornung","year":"2009","unstructured":"Hornung V, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458(7237):514\u20138.","journal-title":"Nature"},{"issue":"6","key":"4380_CR53","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821\u201332.","journal-title":"Cell"},{"issue":"2","key":"4380_CR54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"EK Jo","year":"2016","unstructured":"Jo EK, et al. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13(2):148\u201359.","journal-title":"Cell Mol Immunol"},{"issue":"7329","key":"4380_CR55","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","volume":"469","author":"R Zhou","year":"2011","unstructured":"Zhou R, et al. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469(7329):221\u20135.","journal-title":"Nature"},{"issue":"6","key":"4380_CR56","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.immuni.2013.05.016","volume":"38","author":"R Mu\u00f1oz-Planillo","year":"2013","unstructured":"Mu\u00f1oz-Planillo R, et al. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38(6):1142\u201353.","journal-title":"Immunity"},{"issue":"2","key":"4380_CR57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/1389557515666150909143737","volume":"16","author":"AS Grewal","year":"2016","unstructured":"Grewal AS, et al. Updates on aldose reductase inhibitors for management of diabetic complications and non-diabetic diseases. Mini Rev Med Chem. 2016;16(2):120\u201362.","journal-title":"Mini Rev Med Chem"},{"issue":"9","key":"4380_CR58","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1161\/CIRCRESAHA.109.213447","volume":"106","author":"R Ramasamy","year":"2010","unstructured":"Ramasamy R, Goldberg IJ. Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res. 2010;106(9):1449\u201358.","journal-title":"Circ Res"},{"issue":"8","key":"4380_CR59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0165-6147(94)90010-8","volume":"15","author":"DR Tomlinson","year":"1994","unstructured":"Tomlinson DR, et al. Aldose reductase inhibitors and their potential for the treatment of diabetic complications. Trends Pharmacol Sci. 1994;15(8):293\u20137.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"4380_CR60","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/0002-9343(87)90702-9","volume":"83","author":"P Raskin","year":"1987","unstructured":"Raskin P, Rosenstock J. Aldose reductase inhibitors and diabetic complications. Am J Med. 1987;83(2):298\u2013306.","journal-title":"Am J Med"},{"issue":"42","key":"4380_CR61","doi-asserted-by":"crossref","first-page":"11747","DOI":"10.1021\/acs.jafc.0c05102","volume":"68","author":"C Wang","year":"2020","unstructured":"Wang C, et al. Aldose reductase inhibitor engeletin suppresses pelvic inflammatory disease by blocking the phospholipase C\/protein kinase C-dependent\/NF-\u03baB and MAPK cascades. J Agric Food Chem. 2020;68(42):11747\u201357.","journal-title":"J Agric Food Chem"},{"issue":"3","key":"4380_CR62","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1517\/13543784.2012.656198","volume":"21","author":"S Pandey","year":"2012","unstructured":"Pandey S, et al. A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opin Investig Drugs. 2012;21(3):329\u201339.","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"4380_CR63","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/17460441.2013.843524","volume":"8","author":"M Chatzopoulou","year":"2013","unstructured":"Chatzopoulou M, et al. Development of aldose reductase inhibitors for the treatment of inflammatory disorders. Expert Opin Drug Discov. 2013;8(11):1365\u201380.","journal-title":"Expert Opin Drug Discov"},{"issue":"1","key":"4380_CR64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biocel.2009.09.009","volume":"42","author":"KV Ramana","year":"2010","unstructured":"Ramana KV, Srivastava SK. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol. 2010;42(1):17\u201320.","journal-title":"Int J Biochem Cell Biol"},{"issue":"1\u20133","key":"4380_CR65","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.cbi.2011.02.023","volume":"191","author":"SK Srivastava","year":"2011","unstructured":"Srivastava SK, et al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact. 2011;191(1\u20133):330\u20138.","journal-title":"Chem Biol Interact"},{"issue":"6","key":"4380_CR66","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2165\/00002512-199303060-00007","volume":"3","author":"JW SteeleEpalrestat","year":"1993","unstructured":"SteeleEpalrestat JW, et al. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs Aging. 1993;3(6):532\u201355.","journal-title":"Drugs Aging"},{"issue":"6","key":"4380_CR67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, et al. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"4380_CR68","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","volume":"43","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis. Acta Pharmacol Sin. 2022;43(5):1156\u201366.","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"4380_CR69","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017;66(5):1037\u201346.","journal-title":"J Hepatol"},{"key":"4380_CR70","doi-asserted-by":"crossref","first-page":"154797","DOI":"10.1016\/j.metabol.2021.154797","volume":"120","author":"S Huang","year":"2021","unstructured":"Huang S, et al. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. Metabolism. 2021;120:154797.","journal-title":"Metabolism"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04380-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04380-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:20:26Z","timestamp":1700598026000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04380-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4380"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04380-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"700"}}